Cover Image

The complexity of malignant glioma treatment

Malignant glioma is a highly aggressive, therapeutically non-responsive, and deadly disease with a unique tumor microenvironment (TME). Of the 14 currently recognized and described cancer hallmarks, five are especially implicated in malignant glioma and targetable with repurposed drugs: cancer stem-...

Full description

Saved in:
Bibliographic Details
Main Authors: Kampers, Linde F. C. (Author) , Metselaar, Dennis S. (Author) , Vinci, Maria (Author) , Scirocchi, Fabio (Author) , Veldhuijzen van Zanten, Sophie (Author) , Eyrich, Matthias (Author) , Biassoni, Veronica (Author) , Hulleman, Esther (Author) , Karremann, Michael (Author) , Stücker, Wilfried (Author) , Van Gool, Stefaan W. (Author)
Format: Article (Journal)
Language:English
Published: 4 March 2025
In: Cancers
Year: 2025, Volume: 17, Issue: 5, Pages: 1-35
ISSN:2072-6694
DOI:10.3390/cancers17050879
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers17050879
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/17/5/879
Get full text
Author Notes:Linde F. C. Kampers, Dennis S. Metselaar, Maria Vinci, Fabio Scirocchi, Sophie Veldhuijzen van Zanten, Matthias Eyrich, Veronica Biassoni, Esther Hulleman, Michael Karremann, Wilfried Stücker and Stefaan W. Van Gool
Description
Summary:Malignant glioma is a highly aggressive, therapeutically non-responsive, and deadly disease with a unique tumor microenvironment (TME). Of the 14 currently recognized and described cancer hallmarks, five are especially implicated in malignant glioma and targetable with repurposed drugs: cancer stem-like cells, in general, and glioma stem-like cells in particular (GSCs), vascularization and hypoxia, metabolic reprogramming, tumor-promoting inflammation and sustained proliferative signaling. Each hallmark drives malignant glioma development, both individually and through interactions with other hallmarks, in which the TME plays a critical role. To combat the aggressive malignant glioma spatio-temporal heterogeneity driven by TME interactions, and to overcome its therapeutic challenges, a combined treatment strategy including anticancer therapies, repurposed drugs and multimodal immunotherapy should be the aim for future treatment approaches.
Item Description:Gesehen am 31.07.2025
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers17050879

Similar Items